NO986035L - Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV - Google Patents

Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV

Info

Publication number
NO986035L
NO986035L NO986035A NO986035A NO986035L NO 986035 L NO986035 L NO 986035L NO 986035 A NO986035 A NO 986035A NO 986035 A NO986035 A NO 986035A NO 986035 L NO986035 L NO 986035L
Authority
NO
Norway
Prior art keywords
hiv
combinations
zidovudine
treatment
amino
Prior art date
Application number
NO986035A
Other languages
English (en)
Other versions
NO986035D0 (no
Inventor
Martha Heiden St Clair
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614024.9A external-priority patent/GB9614024D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO986035D0 publication Critical patent/NO986035D0/no
Publication of NO986035L publication Critical patent/NO986035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det beskrives terapeutiske kombinasjoner av [3R*(1R*,2S*)]-[3-[[(4- aminofenyl)sulfonyl](2-metylpropyl)amino]-2-hydroksy-1-fenylmetyl)- propyl]karbaminsyre-tetrahydro-3-furanylester(141W94), 3'-azido-3'-deoksythymidin (zidovudin) og (1S, 4R)-cis-4-[2-amino-6-(cyklopropylamino)-9H-purin-9-yl]-2- cyklopenten-1-metanol (1592U89) som har anti-HIV-aktivitet. Det beskrives også farmasøytiske blandinger som inneholder nevnte kombinasjoner og deres anvendelse ved behandlingen av HIV-infeksjoner, inklusivt infeksjoner med HIV- mutanter som er bærere av resistens overfor nukleosid- og/eller ikke-nukleosid- inhibitorer.
NO986035A 1996-06-25 1998-12-22 Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV NO986035L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217896P 1996-06-25 1996-06-25
GBGB9614024.9A GB9614024D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations
PCT/EP1997/003246 WO1997049410A1 (en) 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv

Publications (2)

Publication Number Publication Date
NO986035D0 NO986035D0 (no) 1998-12-22
NO986035L true NO986035L (no) 1999-02-23

Family

ID=26309631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986035A NO986035L (no) 1996-06-25 1998-12-22 Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV

Country Status (26)

Country Link
US (1) US6486136B1 (no)
EP (1) EP0910386B1 (no)
KR (1) KR20000022225A (no)
CN (1) CN1306430A (no)
AP (1) AP9801418A0 (no)
AT (1) ATE230267T1 (no)
AU (1) AU723877C (no)
BR (1) BR9709951A (no)
CA (1) CA2262765A1 (no)
CO (1) CO4910137A1 (no)
CZ (1) CZ429398A3 (no)
DE (1) DE69718168T2 (no)
EA (1) EA001457B1 (no)
ES (1) ES2189964T3 (no)
HU (1) HUP9903098A3 (no)
ID (1) ID18739A (no)
IL (1) IL127350A0 (no)
IS (1) IS4913A (no)
NO (1) NO986035L (no)
NZ (1) NZ333098A (no)
PE (1) PE87398A1 (no)
PL (1) PL330791A1 (no)
TR (1) TR199802703T2 (no)
WO (1) WO1997049410A1 (no)
YU (1) YU58498A (no)
ZA (1) ZA975565B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
MXPA00012842A (es) * 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV

Also Published As

Publication number Publication date
PL330791A1 (en) 1999-06-07
CN1306430A (zh) 2001-08-01
KR20000022225A (ko) 2000-04-25
ES2189964T3 (es) 2003-07-16
AU3262697A (en) 1998-01-14
EP0910386A1 (en) 1999-04-28
AU723877C (en) 2001-08-23
ZA975565B (en) 1998-12-23
NO986035D0 (no) 1998-12-22
HUP9903098A2 (hu) 1999-12-28
AU723877B2 (en) 2000-09-07
CA2262765A1 (en) 1997-12-31
IL127350A0 (en) 1999-10-28
US6486136B1 (en) 2002-11-26
TR199802703T2 (xx) 1999-03-22
DE69718168D1 (de) 2003-02-06
HU9903098D0 (en) 1999-10-28
WO1997049410A1 (en) 1997-12-31
HUP9903098A3 (en) 2000-01-28
BR9709951A (pt) 1999-08-10
ATE230267T1 (de) 2003-01-15
AP9801418A0 (en) 1998-12-31
CZ429398A3 (cs) 1999-05-12
CO4910137A1 (es) 2000-04-24
EA001457B1 (ru) 2001-04-23
EP0910386B1 (en) 2003-01-02
ID18739A (id) 1998-05-07
EA199801046A1 (ru) 1999-08-26
IS4913A (is) 1998-11-30
YU58498A (en) 1999-11-22
NZ333098A (en) 2000-08-25
DE69718168T2 (de) 2003-10-23
PE87398A1 (es) 1999-01-15

Similar Documents

Publication Publication Date Title
MY115461A (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
ES2614405T3 (es) Composición para proliferación celular
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
NO975585L (no) C-4' modifiserte adenosin-kinase inhibitorer
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
CA2302156A1 (en) Methods for modulating the axonal outgrowth of central nervous system neurons
ES2065914T3 (es) Nucleosidos terapeuticos.
JP2010215648A (ja) コラーゲン産生促進用組成物
Maudgal et al. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis
ES2052732T3 (es) 2',3'-didesoxi-3'-fluorotimidina y compuestos afines para el tratamiento de infecciones por adenovirus.
NO986035L (no) Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i behandling av HIV
BG103959A (en) Carbocyclic nucleoside hemisulphate and its application in the treatment of viral infections
NO995620L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89
Laibson et al. Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic keratitis.
BR9810072A (pt) Formulação farmacêutica semi-sólida contendo dexcetoprofen trometamol
NO995621L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleoid 1592U89
AR007616A1 (es) Combinaciones antivirales
RU93004467A (ru) Замещенные пуриновые арабинозы, их применение, фармацевтическая композиция
Van Haver et al. Transfer factor treatment in MS: A 3 year prospective double-blind study (1982–1985)
FR2863496A1 (fr) Composition therapeutique destinee au traitement des troubles de l'accomodation de l'oeil humain
TH34652A (th) การรวมสารต้านไวรัส

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application